Gastrointestinal Cancer

The complicated nature of gastroesophageal cancer underscores the importance of collaboration between teams to safely treat patients with the disease.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Surgeons and radiation oncologists can collaborate to discuss expected toxicity and surgical outcomes among patients with resectable gastric cancer.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

PFS and response rates were proved to be meaningful among patients receiving zolbetuximab plus mFOLFOX6 and nivolumab for metastatic gastric/GEJ cancer.

Any-grade AEs were observed in 91% of the pembrolizumab arm vs 82% of the placebo arm, with AEs leading to death in 1% of patients in both arms.

Data from the HERIZON-GEA-01 trial may support zanidatamab as a promising new standard in HER2-positive gastroesophageal adenocarcinoma.

Early data from the ABC-HCC trial showed an improvement in median time to failure of strategy with atezolizumab/bevacizumab vs TACE in this HCC population.

Consistent with FGFR2 inhibition, lirafugratinib was well-tolerated among patients with FGFR2-mutated cholangiocarcinoma in the ReFocus trial.

The primary end point of ORR was met in the CAR-like T-cell arm for patients with gastric/GEJ cancer.

The safety profile of chemoradiotherapy with or without tislelizumab was acceptable among patients with gastric cancer or gastroesophageal junction cancer.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Results from arm A of a phase 1/2 trial showed improved efficacy with multi-antigen targeted T cells plus frontline chemotherapy.

Patients with gastric cancer who were treated with a 3-drug antiemetic regimen had lower discontinuation rates following the first zolbetuximab dose.

Overall survival and progression-free survival benefits with the combinations were consistent among prespecified subgroups based on PD-L1 status.

Larger-scale and longer-term studies could elucidate the mechanisms underlying quality of life benefits associated with resistance exercise in this group.

Jose G. Trevino II, MD, FACS, emphasized educating patients and physicians alike to help recognize early signs of pancreatic ductal adenocarcinoma.

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

The approval of durvalumab plus FLOT for patients with resectable gastric/GEJ cancer cements itself as a new standard of care in the space.

Clinicians who are experienced with immunotherapy, like durvalumab, can easily identify and manage AEs associated with treatment for gastric/GEJ cancer.

Based on results from the MATTERHORN study of durvalumab/FLOT in gastric/GEJ cancers, the regimen should be considered a new SOC.

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.